Bulevirtide vs Pasireotide
Overview
Bulevirtide is primarily a antiviral peptide, while Pasireotide is used for hormonal.
This page compares Bulevirtide and Pasireotide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Bulevirtide | Pasireotide | |
|---|---|---|
| Category | Antiviral | Hormonal |
| Regulatory status (US) | FDA approved | FDA approved |
| Typical dosage | — | 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) |
| Frequency | — | Twice daily (SC formulation) or every 4 weeks (LAR formulation) |
| Reported benefits | — | Reduction of cortisol hypersecretion in Cushing's disease, normalization of GH and IGF-1 in acromegaly, pituitary tumor volume reduction, improvement of clinical signs of hypercortisolism |
| Reported side effects | — | Hyperglycemia, new-onset or worsening diabetes mellitus, diarrhea, nausea, cholelithiasis, QT interval prolongation, bradycardia, hepatic enzyme elevation, adrenal insufficiency (hypocortisolism) |
Key differences
Primary use. Bulevirtide is categorised under Antiviral, while Pasireotide falls under Hormonal. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Bulevirtide: FDA-approved. Pasireotide: FDA-approved.
Dosing. Typical dosing for Bulevirtide is not catalogued. Pasireotide is typically dosed at 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) (Twice daily (SC formulation) or every 4 weeks (LAR formulation)).
Can you stack them?
Some protocols combine peptides, but stacking Bulevirtide and Pasireotide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Bulevirtide and Pasireotide?
- Bulevirtide is primarily a antiviral peptide, while Pasireotide is used for hormonal. Bulevirtide is FDA-approved for one or more indications, whereas Pasireotide is FDA-approved for one or more indications.
- What is Bulevirtide used for?
- First/only FDA-approved treatment for chronic hepatitis delta virus (HDV). FDA accelerated approval May 22, 2026. Brand: Hepcludex (Gilead).
- What is Pasireotide used for?
- Multi-receptor somatostatin analog (Signifor/Signifor LAR) FDA-approved for Cushing's disease and acromegaly.
- Can you take Bulevirtide and Pasireotide together?
- Some users combine peptides within a single protocol, but stacking Bulevirtide and Pasireotide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Bulevirtide or Pasireotide FDA-approved?
- Bulevirtide is FDA-approved for one or more indications. Pasireotide is FDA-approved for one or more indications.
Read the full articles
- Bulevirtide — full monograph: mechanism, research, dosing & references
- Pasireotide — full monograph: mechanism, research, dosing & references